A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study

David L. Tait,John A. Blessing,James S. Hoffman,Kathleen N. Moore,Nick M. Spirtos,Jason A. Lachance,Jacob Rotmensch,David S. Miller

Gynecologic Oncology（2011）

引用 39|浏览14

暂无评分

摘要

► Gemcitabine was minimally active in the treatment of advanced endometrial carcinoma. ► The partial response rate was 4% and the stable disease rate was 39%. ► Grade 3 or grade 4 toxicity occurred in 22% of patience.

查看译文

关键词

Gemcitabine,Gemzar,Gynecologic Oncology Group,Endometrial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要